HIV Medicine

Plasma lipid concentrations after 1.5 years of exposure to nevirapine or efavirenz together with stavudine and lamivudine
pp. 347-350(4)
Authors: van Leth, F; Hall, DB; Lange, JMA; Reiss, P

The value of serum albumin in pretreatment assessment and monitoring of therapy in HIV/AIDS patients
pp. 351-355(5)
Authors: Olawumi, HO; Olatunji, PO

Influence of a monocyte chemoattractant protein 1 mutated allele on the response to protease inhibitor-based antiretroviral therapy
pp. 356-360(5)
Authors: Coll, B; Alonso-Villaverde, C; Parra, S; Rabassa, A; Martorell, L; Joven, J; Masana, L

Community-onset methicillin-resistant Staphylococcus aureus in an urban HIV clinic
pp. 361-368(8)
Authors: Skiest, D; Brown, K; Hester, J; Moore, T; Crosby, C; Mussa, HR; Hoffman-Roberts, H; Cooper, T

The impact of highly active antiretroviral therapy on the incidence and outcomes of AIDS-defining cancers in Southern Alberta
pp. 369-377(9)
Authors: Gingues, S; Gill, MJ

Incidence and risk factors of rash associated with efavirenz in HIV-infected patients with preceding nevirapine-associated rash
pp. 378-382(5)
Authors: Manosuthi, W; Thongyen, S; Chumpathat, N; Muangchana, K; Sungkanuparph, S

CD4 percentage is an independent predictor of survival in patients starting antiretroviral therapy with absolute CD4 cell counts between 200 and 350 cells/μL
pp. 383-388(6)
Authors: Moore, DM; Hogg, RS; Yip, B; Craib, K; Wood, E; Montaner, JSG

Abnormal glucose metabolism among older men with or at risk of HIV infection
pp. 389-396(8)
Authors: Howard, AA; Floris-Moore, M; Lo, Y; Arnsten, JH; Fleischer, N; Klein, RS

A randomized, open-label study to compare the effects of two different doses of recombinant human growth hormone on fat reduction and fasting metabolic parameters in HIV-1-infected patients with lipodystrophy
pp. 397-403(7)
Authors: Bickel, M; Zangos, S; Jacobi, V; Lutz, T; Knecht, G; Goebel, F; Staszewski, S; Klauke, S

Prevalence of risk factors for cardiovascular disease in HIV-infected patients over time: the Swiss HIV Cohort Study
pp. 404-410(7)
Authors: Glass, TR; Ungsedhapand, C; Wolbers, M; Weber, R; Vernazza, PL; Rickenbach, M; Furrer, H; Bernasconi, E; Cavassini, M; Hirschel, B; Battegay, M; Bucher, HC

Lymphoid pneumonitis as an immune reconstitution inflammatory syndrome in a patient with CD4 cell recovery after HAART initiation
pp. 411-414(4)
Authors: Ingiliz, P; Appenrodt, B; Gruenhage, F; Vogel, M; Tschampa, H; Tasci, S; Rockstroh, JK

Fulminant toxoplasmosis causing fatal pneumonitis and myocarditis
pp. 415-420(6)
Authors: Eza, DE; Lucas, SB